Weight Gain After Stopping GLP-1? What the Trials Show

"Dr. Alo, I lost 40 pounds on Wegovy. If I stop, will it all come back?"

I get this question every week, and I understand why. These medicines are expensive, the shots are a commitment, and nobody wants to be on a drug forever. So I went back to the trials that actually tested what happens when people stop. The answer is clear, it is a little uncomfortable, and there are good ways to handle it.

Medical note: This article is for general education and is not a substitute for advice from your own doctor. Please do not stop or change a prescribed medicine without talking to them.

Key takeaways

• While people stay on semaglutide (Wegovy) or tirzepatide (Zepbound), the weight loss holds. In one 2-year trial, people on semaglutide were down 15.2% at the end, compared with 2.6% on placebo.
• When people stop, most of the weight comes back. In the STEP 1 extension, about two-thirds of the lost weight returned within a year.
• In the withdrawal trials, people switched to placebo regained 6.9% (semaglutide) and 14.0% (tirzepatide) of their body weight, while those who kept going kept losing.
• Blood pressure, cholesterol and blood sugar improvements drift back too.
• If you have to stop, taper slowly with your doctor and have a plan to restart. A new daily pill, orforglipron (Foundayo), kept far more of the loss than placebo after switching off an injection.

How these medicines work

GLP-1 is a hormone your gut releases after you eat. It tells your brain you are full, slows how fast your stomach empties, and helps your pancreas release insulin. The medicines are long-acting versions of it.

Semaglutide (Wegovy) is a weekly shot. Tirzepatide (Zepbound) is also weekly and works on GLP-1 plus a second gut hormone, GIP. In April 2026 the FDA approved orforglipron (Foundayo), the first daily pill in this class that is not a peptide, for chronic weight management.

Here is the part people miss: these drugs turn down the hunger signal while you take them. They do not permanently reset it. That single fact explains almost everything below.

On the drug, the weight loss holds

The STEP 5 trial followed adults with overweight or obesity, without diabetes, on semaglutide 2.4 mg every week for two full years. At 104 weeks they were down 15.2% of their body weight, compared with 2.6% on placebo, and 77.1% lost at least 5%. Weight loss leveled off around week 60 and then held.

The SELECT trial asked the question I care about most as a cardiologist. In 17,604 adults with heart disease and overweight or obesity, semaglutide cut major cardiovascular events, meaning heart attacks, strokes and cardiovascular deaths, by 20%. The benefit goes beyond the scale.

Figure: weight loss at 2 years on continued semaglutide (STEP 5) and the SELECT heart outcome. Sources: Garvey WT, et al. Nat Med. 2022;28:2083-91; Lincoff AM, et al. N Engl J Med. 2023;389:2221-32.

How to read it: the green bar is the average weight lost after 2 years on semaglutide, 15.2%, against 2.6% on placebo. The navy tiles add that most people lost at least 5%, that the loss leveled off around week 60 and then held, and that in SELECT semaglutide cut major cardiovascular events by 20%.

Stop the drug, and the weight comes back

The best way to test stopping is a withdrawal trial. Everyone takes the drug first. Then half are quietly switched to a placebo, and nobody knows who is who.

In STEP 4, everyone took semaglutide for 20 weeks and lost an average of 10.6%. Over the next 48 weeks, people who kept going lost another 7.9%, while people switched to placebo regained 6.9%. Their waist size and blood pressure moved back up too.

SURMOUNT-4 did the same with tirzepatide. After 36 weeks people had lost an average of 20.9%. Over the next year, those who continued lost another 5.5%, while those switched to placebo regained 14.0% of their body weight.

Figure: weight change after randomization in two withdrawal trials. Sources: Rubino D, et al. JAMA. 2021;325:1414-25 (STEP 4); Aronne LJ, et al. JAMA. 2024;331:38-48 (SURMOUNT-4).

How to read it: everyone lost weight on the drug first. Then, from the dashed line, the green bars show people who kept taking it, who lost a little more, and the pink bars show people quietly switched to placebo, who regained 6.9% (semaglutide) and 14.0% (tirzepatide) of body weight.

The more weight people regained in SURMOUNT-4, the more their blood pressure, cholesterol and blood sugar slipped back. And in the STEP 1 extension, a year after people stopped semaglutide, about two-thirds of the lost weight had returned, along with most of the gains in blood pressure, cholesterol and blood sugar.

Figure: who kept most of their weight loss after stopping. Sources: Aronne LJ, et al. JAMA. 2024;331:38-48 (SURMOUNT-4); Wilding JPH, et al. Diabetes Obes Metab. 2022;24:1553-64 (STEP 1 extension).

How to read it: the bars show how many people kept at least 80% of their weight loss a year later, almost 9 in 10 on tirzepatide and fewer than 2 in 10 on placebo. The circle shows the STEP 1 extension: a year after stopping semaglutide, about two-thirds of the lost weight had come back.

Pooled analyses tell the same story. A 2025 meta-analysis of 8 randomized trials found that regain after stopping was proportional to how much people had lost: about 2.2 kg after liraglutide and about 9.7 kg after semaglutide or tirzepatide. A 2026 meta-analysis of 5 trials found an average rebound of 4.1 kg, with people still about 2.3 kg below where they started. That small leftover benefit is real, but it is small.

Why I treat obesity like high blood pressure

None of this means the medicine failed. It means obesity behaves like a chronic disease. The American Diabetes Association's 2026 Standards of Care call obesity a chronic, relapsing disease, similar to high blood pressure, and say medication usually needs to continue after you reach your goal to keep the weight and the health benefits.

Think about it this way. If your blood pressure is perfect on lisinopril, nobody expects it to stay perfect after you stop the lisinopril. We do not call that a failure. We call it treatment working.

Lifestyle still matters a great deal: protein, strength training, sleep and real food protect muscle and make every dose work better. But a joint advisory from four obesity and nutrition societies noted that no controlled trial has yet shown diet and exercise alone are enough to prevent regain after stopping.

A daily pill to hold the line

Orforglipron changes the conversation for people who want off the shots. In ATTAIN-1, in adults with obesity without diabetes, it lowered weight by 7.0%, 8.4% and 11.4% more than placebo at 6, 12 and 36 mg. In ATTAIN-2, in people with type 2 diabetes, the 36 mg dose produced 9.6% weight loss compared with 2.5% on placebo over 72 weeks.

The most useful trial for my patients is ATTAIN-MAINTAIN, published in May 2026. People who had plateaued on tirzepatide or semaglutide were switched to the orforglipron pill or to placebo for a year.

Figure: share of prior weight loss kept after 52 weeks in ATTAIN-MAINTAIN. Redrawn from Aronne LJ, et al. Nat Med. 2026;32:2679-87.

How to read it: each pair of bars is one group of people who came off an injection. Pink is the daily orforglipron pill, grey is placebo. The pill kept about three-quarters or more of the lost weight; placebo kept about half or less. Remember that no group simply stayed on the injection.

One honest caveat: nobody in that trial simply stayed on the injection, so we do not know how the pill compares with continuing your shot. The follow-up was one year, and side effects were mostly mild to moderate stomach upset.

What I tell my patients

1. Plan for the long term from day one. Assume this is a long-term medicine, the way blood pressure and cholesterol pills are.
2. Protect your muscle. Eat enough protein and lift something two or three times a week. The weight you keep should be muscle, not fat.
3. Never stop cold turkey. If cost, side effects or supply force a change, taper. A viewpoint in JAMA Internal Medicine suggests lowering the dose or spacing out injections over at least 20 weeks, with check-ins that move from weekly to monthly to quarterly.
4. Set a restart line. If you regain more than 5% of your body weight, talk to your doctor about restarting or raising the dose.
5. Ask about the pill. If the shots are the problem, a switch to orforglipron kept far more weight off than stopping did.
6. Keep watching your numbers. Blood pressure, LDL cholesterol and A1c are why we treat weight in the first place, and they drift back if the weight does.

Frequently asked questions

Will I gain all the weight back if I stop Wegovy or Zepbound?
Most people regain a large share. In the STEP 1 extension, about two-thirds came back within a year, and in SURMOUNT-4 fewer than 2 in 10 people switched to placebo kept most of their loss.

How long do I need to stay on a GLP-1?
For most people, long term. The 2026 diabetes Standards of Care treat obesity as a chronic disease and recommend continuing medication after you reach your goal.

Can I lower the dose instead of stopping?
Often, yes, under your doctor's care. A slow taper with close follow-up is far better than stopping all at once, and you can go back up if the weight starts to return.

Do the heart benefits stop if I stop the drug?
In SELECT the heart benefit was seen in people taking semaglutide. When the weight returns after stopping, blood pressure, cholesterol and blood sugar tend to drift back as well, so I would not count on the benefit lasting off the drug.

Is the new pill as good as the shot?
We do not know yet. Orforglipron kept much more weight off than placebo after switching from an injection, but the trial did not compare it with staying on the injection.

The bottom line

GLP-1 medicines work, and they keep working as long as you take them. Stop them, and most of the weight and many of the health gains come back within a year. That is not a reason to avoid them. It is a reason to treat obesity like the chronic disease it is, protect your muscle, and plan any change with your doctor instead of quitting on your own.

Still have questions? Stop Googling and ask Dr. Alo.

You've read the science, but applying it to your own life can be confusing. That's exactly what the Heart 2 Heart VIP Community is for. You can ask me questions directly, join live video calls where we talk through scenarios like this one, and get physician-level guidance based on your actual situation.

Join here: https://dralo.net/community 💪🏻🩺🫀

Dr. Alo

References

1. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4.
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563.
3. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224.
4. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945.
5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. doi:10.1111/dom.14725.
6. Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026;406(10522):2927-2944. doi:10.1016/S0140-6736(25)02165-8.
7. Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine. 2026;32(7):2679-2687. doi:10.1038/s41591-026-04386-7.
8. Mehrtash F, Dushay J, Manson JE. Integrating diet and physical activity when prescribing GLP-1s: lifestyle factors remain crucial. JAMA Internal Medicine. 2025;185(9):1151-1152. doi:10.1001/jamainternmed.2025.1794.
9. American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement 1):S166-S182. doi:10.2337/dc26-S008.
10. US Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book): orforglipron (Foundayo).